Abstract
Glucagon-like peptide-1 (GLP-1) is the main member of the incretin family and stimulates insulin secretion by binding with its specific receptor on pancreatic β-cells. In addition, GLP-1 exerts broad beneficial effects on the glucose regulation by suppressing food intake and delaying stomach emptying. Now, long acting GLP-1 analogs including exenatide and liraglutide have been approved for the treatment of diabetes mellitus type 2, however long-term injection can limit their use for these chronic patients. In this report, the authors provide a review on the development of non-peptide GLP-1 receptor agonists and introduce a novel agonist DA-15864.
MeSH terms
-
Animals
-
Diabetes Mellitus, Type 2 / drug therapy*
-
Drug Design
-
Glucagon-Like Peptide 1 / analogs & derivatives
-
Glucagon-Like Peptide 1 / metabolism
-
Glucagon-Like Peptide 1 / pharmacology*
-
Glucagon-Like Peptide 1 / therapeutic use
-
Glucagon-Like Peptide-1 Receptor
-
Humans
-
Hypoglycemic Agents / pharmacology*
-
Hypoglycemic Agents / therapeutic use
-
Insulin / biosynthesis
-
Insulin-Secreting Cells / drug effects*
-
Insulin-Secreting Cells / physiology
-
Molecular Targeted Therapy*
-
Rats
-
Receptors, Glucagon / agonists*
-
Receptors, Glucagon / metabolism
Substances
-
GLP1R protein, human
-
Glp1r protein, rat
-
Glucagon-Like Peptide-1 Receptor
-
Hypoglycemic Agents
-
Insulin
-
Receptors, Glucagon
-
Glucagon-Like Peptide 1